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Abstract
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OBJECTIVE—Gamma Knife radiosurgery (GKRS) is frequently used to treat residual or
recurrent nonfunctioning pituitary macroadenomas. There is no consensus as to whether GKRS
should be used early after surgery or if radiosurgery should be withheld until there is evidence of
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imaging-defined progression of tumor. Given the high incidence of adenoma progression after
subtotal resection over time, the present study intended to evaluate the effect of timing of
radiosurgery on outcome.
METHODS—This is a multicenter retrospective review of patients with nonfunctioning pituitary
macroadenomas who underwent transsphenoidal surgery followed by GKRS from 1987 to 2015 at
9 institutions affiliated with the International Gamma Knife Research Foundation. Patients were
matched by adenoma and radiosurgical parameters and stratified based on the interval between last
resection and radiosurgery. Operative results, imaging data, and clinical outcomes were compared
across groups following early (≤ 6 months after resection) or late (> 6 months after resection)
radiosurgery.

Author Manuscript

RESULTS—After matching, 222 patients met the authors’ study criteria (from an initial
collection of 496 patients) and were grouped based on early (n = 111) or late (n = 111) GKRS
following transsphenoidal surgery. There was a greater risk of tumor progression after GKRS (p =
0.013) and residual tumor (p = 0.038) in the late radiosurgical group over a median imaging
follow-up period of 68.5 months. No significant difference in the occurrence of post-GKRS
endocrinopathy was observed (p = 0.68). Thirty percent of patients without endocrinopathy in the
early cohort developed new endocrinopathies during the follow-up period versus 27% in the late
cohort (p = 0.84). Fourteen percent of the patients in the early group and 25% of the patients in the
late group experienced the resolution of endocrine dysfunction after original presentation (p =
0.32).

Author Manuscript

CONCLUSIONS—In this study, early GKRS was associated with a lower risk of radiological
progression of subtotally resected nonfunctioning pituitary macroadenomas compared with
expectant management followed by late radiosurgery. Delaying radiosurgery may increase patient
risk for long-term adenoma progression. The timing of radiosurgery does not appear to
significantly affect the rate of delayed endocrinopathy.
Keywords
stereotactic radiosurgery; Gamma Knife; pituitary surgery; transsphenoidal surgery;
macroadenoma; nonfunctioning pituitary adenoma

Author Manuscript

Nonfunctioning pituitary adenomas (NFPAs) account for approximately 15%–30% of all
pituitary tumors and typically grow slowly before the patient presents with visual deficits,
headache, and hypopituitarism from compression of the optic apparatus and normal pituitary
gland.9,14 Transsphenoidal surgery and decompression of the optic chiasm is highly effective
in providing symptomatic relief and the possibility of a long-term cure, but historic rates of
total resection vary substantially. Complete resection can be limited due to adenoma volume
and propensity for microscopic infiltration of the surrounding architecture.3,5,28,29,41,55
With the advent of transsphenoidal techniques, the distant consequences of slow-growing
pituitary tumors have emerged. Long-term outcomes of surgically treated NFPAs
demonstrate that tumor recurrence at distant follow-up can be upwards of 20% after grosstotal resection6–8, 12, 17, 19,31,41,43,58,64,66 and 50%–60% after subtotal resection without
adjuvant treatment.6–8,12,17,19,20,31,41,43,44,58, 64,66 The modern surgical armamentarium may
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afford more options for patients with nonfunctioning tumors, including secondary operations
and/or adjuvant treatment of residual or progressive disease.8
Standard management options for residual or recurrent NFPAs range from expectant
management with serial clinical and imaging follow-up to repeat adenomectomy and/or
stereotactic radiosurgery (SRS). Furthermore, for adenomas that invade laterally beyond the
medial wall of the cavernous sinus, aggressive debulking can pose undue risk to
neurovascular structures. In these latter cases (subtotal resections and recurrent
nonfunctioning macroadenomas), SRS has been repeatedly reported as a clinically safe and
scientifically viable management option.4,21–25, 30,32, 35, 42,44–46,49,50,52,62,65 SRS helps
reduce the conventional risks of radiotherapy, including hypopituitarism, radiation-induced
tumors, carotid stenosis, and stroke, as well as neurocognitive side effects.2,27,36,37,55
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The utility of SRS in treating residual and recurrent adenomas has been demonstrated across
various large patient series with tumor control rates approaching 90%.42,50 One of the
largest multicenter studies included 512 patients treated with GKRS and demonstrated
overall tumor control in 93.4% of patients at last-follow-up with actuarial tumor control
rates of 98%, 95%, 91%, and 85% at 3, 5, 8, and 10 years postradiosurgery, respectively.52
Despite mounting evidence of the long-term efficacy of SRS, the inherent tradeoff between
potential treatment complications and residual tumor growth has limited the understanding
of and consensus for radiosurgery along the spectrum of disease and therapy. Clinicians
often face difficult decisions regarding administering SRS early after initial transsphenoidal
debulking or after some time of expectant management during which the patient experiences
further adenoma growth.
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Importance of Study
To the best of our knowledge, this is the largest multicenter matched-cohort review with
long-term clinical and radiological follow-up for comparing radiosurgery for pituitary
macroadenomas based on the time interval from subtotal resection. The present study
evaluated a large patient cohort from multiple institutions to better elucidate safe and
effective treatment strategies following subtotal resection of NFPAs and the risk-benefit
tradeoff of additional procedures versus expectant management. Early GKRS appears to
decrease the risk of imaging-defined progression of subtotally resected tumors compared
with expectant management. The timing of adjuvant GKRS does not appear to significantly
affect the rate of postradiosurgical endocrinopathy over the long-term.

Author Manuscript

The lack of consensus for the timing of SRS for residual adenoma stems largely from
concern for radiation-induced endocrinopathy. The present study represents a multicenter
attempt to validate a prior single-institution study of a matched cohort of 64 patients in
which differences in early versus late GKRS outcomes were observed. 47 The purpose of
this review is to more comprehensively evaluate a large patient cohort from multiple
institutions to better elucidate safe and effective treatment strategies following subtotal
resection of NFPA and the risk-benefit profile of early intervention with radiosurgery versus
expectant management.
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Methods
Data Collection
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Nine medical centers affiliated with the International Gamma Knife Research Foundation
received respective institutional review board approvals to submit outcomes analyses of
patients who underwent transsphenoidal surgery followed by GKRS for residual
nonfunctioning pituitary macroadenoma. The following centers contributed data: University
of Pittsburgh Medical Center (110 patients), NYU Langone Medical Center (14), Taipei
Veterans General Hospital (114), Na Homolce Hospital Prague (73), Cleveland Clinic
Foundation (45), Universite de Sherbrooke (27), Beaumont Health System (53), West
Virginia University (7), and University of Virginia (64). All patients who received GKRS
after subtotal resection during the period from 1987 to 2015 were evaluated for inclusion in
this study. A database with predefined variables was created at the University of Virginia and
sent to all participating centers that then subsequently reviewed patient medical records and
entered data into the spreadsheet. Under institutional review board approval, pooled and deidentified data were screened by an independent third party and transmitted to the first
author who drafted this report on behalf of the International Gamma Knife Research
Foundation. In total, 496 patients were treated with GKRS for residual tumors. Patients who
presented with hormonally active tumors and/or an unknown histological subtype (146
patients) were excluded. Patients with unknown information regarding the interval between
surgery and GKRS and/or follow-up were also excluded (10 patients). Of the remaining 340
patients with adequate presenting and follow-up information, patients were subsequently
matched on the basis of histological subtype, GKRS target volume, margin dose, and
maximum dose. This yielded a final analysis of 222 patients. All of the patients included in
this review demonstrated residual adenoma after resection and before GKRS treatment. Data
were collected prospectively and reviewed retrospectively, including baseline demographics,
symptoms, imaging reports before and after surgery, treatment information, histology
reports, and clinical notes during the course of follow-up.
Patient Evaluation

Author Manuscript

Before surgery all patients underwent evaluation, which included MRI and neurological and
endocrinological examinations. Clinical examination, including serum testing for pituitary
function and/or formal ophthalmological visual field testing, was performed according to
and varied by institutional practice. NFPAs were defined before surgery by imaging (e.g.,
sellar mass > 1 cm) and clinical and biochemical characteristics to preclude a diagnosis of a
functioning tumor caused by a condition such as Cushing’s disease, acromegaly, or
prolactinoma (e.g., nonappreciably elevated serum levels of prolactin [< 200 ng/ml],
adrenocorticotrophic hormone [ACTH], growth hormone, and insulin-like growth factor 1).
During the interval between surgery and GKRS, patients were again evaluated with imaging
and on a neurological and endocrine basis. For planning purposes, patients underwent
stereotactic MRI or CT at the time of GKRS. This information served as the baseline data
for comparing longer-term clinical and imaging outcomes.

J Neurosurg. Author manuscript; available in PMC 2019 September 01.

Pomeraniec et al.

Page 5

Clinical and Radiological Follow-Up

Author Manuscript
Author Manuscript

Patients were routinely followed up in the clinic with neurological examinations, endocrine
evaluations, and biochemical assays and imaging of the sella (typically MRI). Whenever
possible, patients underwent follow-up examination, endocrine testing, and neuroimaging at
their respective treatment center. However, because all institutions were referral centers for
broad geographic areas, some patients underwent follow-up evaluations by their referring
physicians. In those cases, clinical notes, laboratory tests, and neuroimaging studies were
sent to and reviewed by the treating neurosurgeons who performed GKRS. The follow-up
images were compared with the images obtained at the time of GKRS. Comprehensive
follow-up neurological and ophthalmological assessments served to evaluate new symptoms
or progressive neurological deficits. Tumor response to treatment was demonstrated on serial
neuroimaging (independently reviewed at the respective treatment centers), and endocrine
testing was matched to these follow-up time points. Clinical and imaging outcomes were
determined at 3 time points: after surgery, before GKRS, and at the last available
examination. Tumor dimensions were measured in the axial, sagittal, and coronal planes.
The dimensional indices of the tumors were measured and recorded in 3 orthogonal planes:
transverse (TR), anteroposterior (AP), and craniocaudal (CC). The volumes of the tumors
were estimated using the following formula: V = (π × [TR × AP × CC])/6.1,33 A change in
tumor size was defined as a 15% or greater increase or decrease in tumor volume.53
Adenomas that changed in volume by less than 15% were considered stable. New
endocrinopathy was defined objectively by hormonal assays and physician recommendation
for medical hormone replacement therapy.
Radiosurgical Technique

Author Manuscript
Author Manuscript

Models U, B, C, 4C, and Perfexion Gamma Knife units (Elekta AB) were used depending
on the technology available and the time of treatment at the various participating centers.
The radiosurgical techniques have been well detailed.49,54,62 The procedure was performed
using Leksell Gamma Unit (Elekta AB) model U before 2001 and model C thereafter with
GammaPlan software (Elekta AB). Stereotactic Leksell G-frame placement was performed
in the operating room under local anesthesia with or without additional intravenous
conscious sedation. Following frame placement, treatment planning included high-resolution
stereotactic MRI with pre- and postcontrast thin-slice (1-mm-thick) axial and coronal images
through the sella with fat suppression as needed. For patients with rare contraindications to
MRI, thin-slice stereotactic CT scans were obtained instead. SRS and dose planning were
subsequently performed in consultation with a neurosurgeon, radiation oncologist, and
medical physicist.52,56 At each center, dose selection was based on a complex iteration of
tumor volume, contiguity to the optic apparatus, and history of exposure to fractionated
radiation therapy.
Statistical Analysis
Statistical analyses were performed using R (2014) (R Foundation for Statistical
Computing). All statistical tests were 2-sided. For all statistical tests, a p value ≤ 0.05 was
considered significant. In general, data are presented as the frequency for categorical
variables and as the mean with SD or median with range for continuous variables.
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Propensity score matching in a 1:1 fashion was conducted with nearest-neighbor matching,
and patients with nonfunctioning pituitary macroadenomas who underwent GKRS within 6
months following the last resection (early GKRS cohort) were matched and blinded to the
outcomes of the delayed group (late GKRS cohort), which included patients who underwent
GKRS later than 6 months after last resection. Matching was conducted based on the
following parameters: null cell, gonadotroph, thyrotroph, somatotroph, silent ACTH staining
of a previously resected tumor, age at GKRS, target volume at GKRS, and radiosurgical
margin dose.

Author Manuscript

Categorical data were compared between the 2 cohorts using Pearson’s chi-square test, and
continuous data were compared using the Student t-test. Kaplan-Meier analysis was
performed with the log-rank test to determine the statistical significance of the actuarial
tumor progression rate over time after radiosurgery. Univariate Cox proportional hazards
regression analysis was performed on the early and late GKRS cohorts, and age at GKRS
and the radiosurgical variables were used to determine the factors significantly associated
with the tumor progression rate. Three hundred fifty-seven patients had complete data
regarding histological staining. Following propensity score matching, 111 patients
comprised each group.

Results
Patient Demographics and Presenting Symptoms
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After matching, a total of 222 patients met the study criteria and were included in the
analysis. Forty-seven patients (21.2%) from the prior single-institution study were included.
Patients were stratified into 2 cohorts based on the interval between resection and
radiosurgery: early (≤ 6 months) (n = 111) and late (> 6 months) (n = 111) groups. The
average ages at transsphenoidal surgery and GKRS were 51.1 years and 53.0 years,
respectively. In total, 31 patients underwent more than 1 resection before radiosurgery: 22
patients underwent 2 resections and 9 patients underwent 3 resections. The median clinical
and imaging follow-up periods were 62.3 months and 51.6 months, respectively (Table 1).
The vast majority of the 222 total patients presented with symptoms commonly associated
with pituitary macroadenoma. Only 9 patients in the early cohort and 3 patients in the late
cohort presented with incidental findings observed on imaging for unrelated clinical workup.
For symptomatic patients, visual disturbance was the most common presenting symptom (n
= 139; 62.6%) followed by headache (n = 122; 55.0%), fatigue and weakness (n = 41;
18.5%), and sexual dysfunction (n = 27; 12.2%). Endocrine function at presentation was
determined by a combination of serum hormone levels and/or patient medications. Sixty
patients (27.1%) presented with prior endocrinopathy. The only difference in symptoms at
presentation was fatigue and weakness (24.3% in the early group vs 12.6% in the late
group). Significantly more patients in the early cohort presented with hypothyroidism
(18.9% of the early group vs 7.2% of the late group), and there were no other differences in
presenting endocrine function between groups (Table 1).
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Tumor Characteristics at the Time of Initial Presentation for Resection
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All tumors at the time of surgery were macroadenomas and classified according to their
volumetric dimensions, extent of invasion into surrounding structures, and histopathologic
characteristics (Table 2). Preoperatively, most tumors (60.4% of the early cohort and 39.6%
of the late cohort) measured 2–4 cm in maximum diameter. There was no difference in
average tumor volume between the early cohort (12.4 cm3; range 1.0–100.4 cm3) and the
late cohort (13.4 cm3; range 1.0–115.0 cm3). Thirty-seven (33.3%) tumors measured > 10
cm3 in the early cohort versus 35 (31.5%) in the late cohort. The majority (79.7%) of
patients had tumors with a suprasellar component, and 161 patients (72.5%) exhibited
involvement of the cavernous sinus (78.4% in the early group vs 66.7% of the late group; p =
0.07). Histologically, adenomas were most commonly null cell (n = 113; 50.9%) followed
by gonadotrophic (28.4%) and silent corticotrophic tumors (21.2%). There were no
significant differences in the histopathologic findings between groups after matching.

Author Manuscript

Surgical Outcomes After Resection
Transsphenoidal surgery achieved average tumor reductions of 66.2% (8.3 cm3) and 78.7%
(10.7 cm3) in the early and late cohorts, respectively. At 2 months following surgery, most
patients (n = 159; 71.6%) exhibited residual tumor with no statistical difference between
groups (p = 0.79). There was no difference in average residual tumor volume at that time
(4.1 cm3 in the early group [n = 89] vs 2.7 cm3 in the late group [n = 70]; p = 0.16). Of 60
patients, 11 (18.3%) experienced resolution of preoperative endocrinopathy. Resolution of
preexisting endocrinopathy (p = 1.00) or the development of new endocrinopathy after
surgery (p = 0.63) did not differ between groups (Table 3).
GKRS Parameters

Author Manuscript
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In the early cohort, median time to radiosurgery from prior resection was 4.0 months (range
0.1–6.0 months). In the late cohort, median time to radiosurgery from resection was 19.9
months (range 6.1–156.4 months). In the late cohort, 35 patients (31.5%) received treatment
within 6–12 months after subtotal resection, 25 (22.5%) patients received treatment within
12–24 months, and 51 patients (46.0%) received treatment > 24 months after subtotal
resection. There were no significant differences in radiosurgical parameters between groups.
The median maximum dose to the tumor was 29 Gy across both cohorts (range 10–50 Gy).
The median tumor margin dose was 15 Gy (range 5–25). The target volume was on average
higher in the early cohort (5.7 cm3) than the late cohort (5.3 cm3), but without significant
difference (p = 0.67). The maximum dose to the visual pathways (optic apparatus) was
typically limited to a median of 7.2 Gy (range 1.0–13.7 Gy) (Table 4). To limit radiation to
the optic apparatus, shielding was employed as needed.
Radiological Outcome
Patients in the early cohort had an average of 46.5 months of imaging follow-up after
transsphenoidal resection (range 5.3–194.2 months) and 40.3 months after GKRS (range
2.8–189.2 months). Patients in the late cohort had an average of 82.9 months of imaging
follow-up after transsphenoidal resection (range 13.1–214.3 months) and 49.8 months after
GKRS (range 2.5–181.1 months), with the increase in follow-up being a result of the
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extended interval between resection and time to SRS. In the early cohort, 30 patients
(27.0%) received > 5 years and 6 patients (5.4%) received > 10 years of imaging follow-up.
In the late cohort, 71 patients (63.9%) received > 5 years and 26 patients (23.4%) received >
10 years of imaging follow-up. More patients in the late cohort (n = 76; 93.8%)
demonstrated residual tumor on imaging at the last follow- up versus the early cohort (n =
81; 83.5%) (p = 0.038). While most (82.2%) residual tumors (81.5% in the early group and
82.9% in the late group) did not significantly change in size over this follow-up period, there
was a greater risk of tumor progression after GKRS in the late treatment group (p = 0.013
according to the log-rank test) over the median neuroimaging follow-up of 64.8 months. The
actuarial adenoma progression rates were 2.8%, 6.1%, and 9.1% at 2 years, 4 years, and 6
years following SRS in the early cohort, respectively, while the rates were 7.8%, 14.3%, and
21.2%, respectively, in the late cohort (Fig. 1). The late cohort exhibited a significantly
higher proportion of residual tumor at last follow-up (p = 0.038) as well as tumor growth or
new tumor residual relative to postoperative imaging (Table 5).
Endocrine Outcome
Pituitary insufficiency was observed in 108 of 222 patients (48.6%) at the time of GKRS (p
= 0.89). There was no significant difference between groups in the proportion of patients
without endocrinopathy before GKRS who subsequently developed new endocrinopathy
during the follow-up period: 6 of 51 patients (11.8%) in the early cohort compared with 5 of
53 patients (9.4%) in the late cohort (p = 0.76). This was also true regarding new
endocrinopathies after presentation (before transsphenoidal resection): 19 patients (30.2%)
in the early cohort compared with 15 patients (26.8%) in the late cohort (p = 0.84). There
was no difference in endocrinopathy at last clinical follow-up (58.7% of the early cohort vs
55.5% of the late cohort; p = 0.68) (Table 5).

Author Manuscript

There was also no difference in resolved endocrinopathy across groups: 13.9% after
presentation and 10.0% after GKRS in the early group compared with 25.0% after
presentation (p = 0.32) and 12.1% after GKRS (p = 0.78) for the late group. Improvement in
endocrinopathy was analyzed with more granularity by type, including hypogonadism,
hypocortisolism, hypothyroidism, and panhypopituitarism. In the early group, 1 patient with
hypogonadism, 5 patients with hypocortisolism, 2 patients with hypothyroidism, and 2
patients with panhypopituitarism had improvement or resolution after GKRS. In the late
cohort, 6 patients with hypogonadism, 2 patients with hypocortisolism, 2 patients with
hypothyroidism, and 2 patients with panhypopituitarism showed evidence of clinical
resolution. Resolution of symptoms did not differ across groups (Table 5).

Author Manuscript

Discussion
NFPAs, which are hormonally quiescent and typically slow growing, can expand
significantly and alter pituitary function by compressing normal glandular tissue.11,61
Transsphenoidal surgery has become a mainstay of effective treatment for NFPA and can be
curative for some patients. Still, technical difficulty and potential undue risk often preclude
complete resection of locally invasive adenomas (i.e., adenomas that invade the cavernous
sinus, sphenoid bone, or diaphragm sella).40 SRS has been shown to be a safe and effective
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adjuvant therapy for residual adenomas or progressive disease not amenable to gross-total
resection by surgery alone (and, in rare cases, as initial treatment). Despite moderate
advances in the modal spectrum of such therapy, significant cumulative lifetime morbidity
presents a real clinical burden for both therapeutic regimens.55
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The current study draws from 9 different institutions and includes a matched cohort of 222
patients who underwent transsphenoidal surgery followed by GKRS for residual
nonfunctioning pituitary macroadenomas. All patients had residual tumor observed at the
time of resection. GKRS was performed as an adjunct therapy in cases of residual adenomas
that were observed on serial neuro-imaging after resection or exhibited local invasion to the
cavernous sinus, bone, or dura, or GKRS was performed when recurrence was reasonably
and clinically ascertained by the return of symptoms and the tumor was considered unlikely
to respond to additional resection.34 As a multiinstitutional follow-up to a prior study of 64
patients at the University of Virginia that revealed early GKRS within 6 months of resection
was associated with less risk for tumor progression and endocrinopathy, a similar time frame
was analyzed.47 This time interval permits patients to recover from surgery, postsurgical
changes on MRI to subside, and more optimal imaging for radiosurgical targeting purposes.
Patients who exhibit equivocal changes on MRI at 2–3 months following surgery are
typically followed up with routine care and subsequent imaging over the next 3–5 months.
This contemporary treatment paradigm offers natural allocation between the early (≤ 6
months) and late (> 6 months) patient cohorts.
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In concordance with the previous single-center study, early GKRS demonstrated better
tumor control compared with expectant management followed by radiosurgery.47 In the prior
study, early GKRS conferred significantly higher radiological resolution of the residual
tumor (median maximum dose of 32 Gy and tumor margin dose of 16 Gy across both
cohorts); however, this was not observed in this multiinstitutional study. One possible
explanation for the long-term radiological differences between the early and late treatment
groups rests with the inherent tumor characteristics. If patients with growing adenomas are
in fact harboring more aggressive yet ill-defined tumor biology, then these adenomas could
be less effectively controlled by GKRS. Still, tumor biology (beyond type and subtype of
adenoma) did not necessarily differ between the early and late cohorts because patients were
effectively matched for these criteria. Early GKRS (within 6 months after resection) may
simply not offer enough time for patients with most adenomas to reliably demonstrate tumor
growth. Alternately, because volume is well known to affect outcomes in SRS, the larger
volume adenoma may be less effectively controlled. However, there were no differences in
the average tumor volume treated, either preoperatively or at the time of GKRS (or any other
radiosurgical parameters), between the 2 groups.
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Subtotal resection without adjuvant treatment reportedly results in high recurrence rates of
50%–60% within 10 years of surgery.8,20,31,41,43,45 More recent investigations and metaanalyses place the incidence of macroadenoma growth at 12.5 per 100 person-years.16
O’Sullivan et al. studied 159 patients with nonfunctioning adenomas who underwent
resection without adjuvant radiation or radiosurgery and found tumor growth or recurrence
in 33.5% of patients at a median follow-up of 4.1 years (range 1–20.7 months). The 5- and
10-year actuarial rates of recurrence or growth of residual adenoma were 24.4% and 51.5%,
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respectively. 41 This is consistent with other surgical series that suggest 10-year recurrence
rates ranging from 19% to 78% after resection.10,11,41,42,59 Because recurrence is
recognizably common after subtotal surgical resection, other techniques such as
radiosurgery have been effective in treating patients with aggressive neuropathological
attributes (such as silent ACTH-secreting adenomas) and in younger populations with
recurrent or residual tumors.52

Author Manuscript
Author Manuscript

SRS offers a high rate of tumor control, with most studies citing a 90% control rate with a
low rate of new neurological or endocrinological deficits.
4,13, 15,18,21–26,30,32,35,38,39,42,44–46, 48, 49,52,55,61,63,65 SRS has also become widely
recognized as a reasonable alternative to repeat resection and fractionated radiation therapy.
52 Nonetheless, the promise of GKRS has been tempered in practice due to results being
largely reported from single-center retrospective studies.
4,15, 18,21–26,30,32,35,39,42,44–46,49,54, 61,65 Despite favorable data from contemporary largescale multicenter studies, the optimal role and timing of GKRS for patients with recurrent or
residual growing NFPAs remains uncertain.52 In a recent series of 140 consecutive patients
with nonfunctioning pituitary macroadenomas treated with GKRS at the University of
Virginia, the overall tumor control and actuarial 5-year progression-free survival rates were
90% and 97%, respectively. Tumor control correlated directly with radiosurgical target
volume, which testifies to the lasting effects of microsurgical resection prior to GKRS for
macroadenomas.55 This purview was partially laid out by Mingione et al. in 2006, who
proposed a propensity for nonfunctioning pituitary macroadenomas to either grow or
decrease over longer follow-up periods.35 Comparable long-term effectiveness of GKRS was
achieved by Park et al. who demonstrated a 90% tumor control rate in 125 patients with
nonfunctioning adenomas over a mean follow-up of 62 months.42 Gopalan et al. achieved a
tumor control rate of 83% over a median follow-up of 95 months.18 These studies were
similar in suggesting that tumor volume predicted neurological decline, including delayed
hypopituitarism. 35,42,55 One may reason that providing suboptimal radiosurgical doses to
larger adenomas in close proximity to radiation-sensitive structures may allow for tumor
growth after GKRS.

Author Manuscript

Residual pituitary adenomas tend to progress slowly over time without further radiosurgery.
Despite this commonality, some patients with residual disease never exhibit
radiological or clinical progression despite long follow-up intervals. The timing of adjuvant
therapy aside, clinicians may not be able to predict with any reasonable reliability those
patients who will have stable tumor volume after subtotal resection alone from those who
will have progressive tumor growth over a shorter interval after surgery. A central and
persistent contention against early GKRS rests on the basis that many residual adenomas
may not in fact progress and that such treatment would need-lessly expose patients to
potential complications. Additionally, there is debate regarding the effectiveness of GKRS
for actively growing adenomas relative to radiologically stable ones.
47,52

The current study offers another salient observation and departure from prior findings of
long-term endocrinopathy based on the interval between last subtotal resection and GKRS.
In the previous study, late adjuvant GKRS treatment was associated with significantly higher
rates of endocrinopathy secondary to higher rates of tumor growth during the observational
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period prior to GKRS.47 Patients in the late cohort (64%) without baseline endocrinopathy
were more likely to develop new endocrinopathy following radiosurgery relative to the early
cohort (17%).47 In the current study, this difference disappeared both in terms of new
endocrinopathy after presentation (30% of patients in the early cohort vs 27% of patients in
the late cohort) and after GKRS (12% of patients in the early cohort vs 9% of patients in the
late cohort). Fifty-nine percent of patients in the early cohort and 56% of patients in the late
cohort experienced endocrine dysfunction at the last clinical follow-up (p = 0.68). The rates
of new endocrinopathy after presentation (p = 0.84), new endocrinopathy after GKRS (p =
0.76), and resolved endocrinopathy after presentation (p = 0.32) and GKRS (p = 0.78) were
comparable between groups.

Author Manuscript
Author Manuscript

The present study draws from several unique strengths, including the large number of
patients drawn from multiple institutions and the longitudinal nature of the follow-up
relative to other reports in the literature. To the best of our knowledge, this is the largest
multicenter matched-cohort study to use propensity scorematching to reduce bias. Despite
these efforts, this study is not without weakness. As a retrospective analysis with inherent
referral pattern bias for both the patient and clinician, the selection criteria and doseplanning techniques were nonuniform across treatment centers. Patient bias could have been
introduced by preferring early treatment versus opting to be followed for a longer period
before electively proceeding with radiosurgery. We can also now use more modern SRS
devices to administer hypofractionated treatments to treat some larger adenomas and more
optimally deliver an effective margin dose to the tumor while still respecting constraints to
critical structures (e.g., the optic apparatus). Comparing visual function after surgery and
radiosurgery and over the long term would also yield valuable insight into the symptomatic
course; unfortunately, while we did have reliable visual function data across all participating
sites, formal visual field and acuity testing was not performed uniformly or regularly at some
centers. Finally, the median follow-up was 5.2 years and some patients had a relatively short
follow-up, which may have precluded complete assessment of delayed endocrine
dysfunction and/or tumor control.

Author Manuscript

While the preresection and preradiosurgical growth rates were not the focus of the study,
further tumor classification might provide valuable insight into the differences observed
between the 2 groups. All of the patients in this study harbored histologically confirmed
NFPAs. The Ki-67 rates were not reliably collected for all patients in this review, but Ki-67
tends to be low in nonfunctioning adenomas. In a study by Thapar et al., the mean growth
fraction for nonfunctioning adenomas was 2.09%, while functioning adenomas had a growth
rate of 3.25% and pituitary carcinomas had 11.91%.57 Most series have shown no difference
in tumor control after SRS in functioning versus nonfunctioning adenomas.51 Thus, even if
these nonfunctioning adenomas exhibited a slightly higher Ki-67 rate than typical that
placed them at the level of functioning adenomas, growth control after radiosurgery should
still have been high because achieving growth control in functioning adenomas with
radiosurgery is quite likely. The nonfunctioning adenomas herein were not pituitary
carcinomas, which respond less well to ionizing radiation, and no pituitary carcinomas were
included in the study.
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The 6-month time interval of the current analysis was based on the findings of a prior singleinstitutional study.47 Unfortunately, given the variability in the timing of SRS in the late
group, finding an adequate later time point that would allow for case matching in the current
cohort is not practical. The 6-month cutoff point may in fact be arbitrary, and findings
simply suggest a difference in outcome with earlier versus later treatment. Further studies
are required to better define the point at which SRS is given after resection that will result in
a worse outcome to the patient. Testing multiple time points would likely require a more
prospective study or at least multiple matched analyses, which goes beyond the presently
available data for this multicenter group.

Author Manuscript

Patients in the late treatment cohort were treated for a multitude of reasons including tumor
presence, symptomatic presence (e.g., headaches), patient preference in the setting of
persistent disease, and tumor progression. This could have introduced bias if the analyses
were not matched for tumor volume and pre-GKRS endocrinopathy between the early and
late treatment groups. Adenoma volume and preexisting endocrinopathies have been shown
to impact post-GKRS outcomes. Because these factors were matched, they should not have
led to the observed differences in outcome. Nevertheless, we acknowledge that selection
biases or the inherent failings of a propensity matched analysis could have led to unintended
biases in the results.

Author Manuscript

This is a multiinstitutional matched-cohort review and does not substitute for prospective
trials. Further prospective studies, or analysis of data accrued by large, prospective registries
with propensity score matching along with central radiographic review, would more
definitively unearth any differences in tumor control and endocrine outcomes based on
treatment timing. Innovations in treatment modalities and providing patient care would
assuredly benefit from more interdisciplinary and longitudinal follow-up studies of the
natural history of surgically treated tumors.

Conclusions
In the largest multicenter matched-cohort review of adjuvant GKRS for nonfunctioning
pituitary macroadenomas to date, early GKRS is associated with a decreased risk of
imaging-defined progression of subtotally resected tumors compared with expectant
management. The timing of adjuvant GKRS does not appear to significantly affect the rate
of postradiosurgical endocrinopathy over the long term.
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adrenocorticotrophic hormone
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FIG. 1.

Kaplan-Meier plot of tumor progression over time. This plot compares the cumulative tumor
failure rate over time between the early (GKRS ≤ 6 months after resection) and late (GKRS
> 6 months after resection) groups.
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Patient demographics
Characteristic

Early GKRS (≤6 mos)

Late GKRS (>6 mos)

No. of patients

111 (50.0)

111 (50.0)

Male

43 (38.7)

48 (43.2)

Female

47 (42.3)

53 (47.7)

Unknown

21 (18.9)

10 (9.0)

Surgery

52.5 (12.4)

49.7 (12.5)

GKRS

53.3 (12.4)

52.6 (13.2)

p Value

Sex
1.00

Age at procedure, mean (SD), yrs

Follow-up after last trans-sphenoidal resection, median (range), mos

Author Manuscript

Clinical

42.2 (5.6–202.4)

85.6 (9.1–217.0)

Imaging

37.8 (5.3–194.2)

75.1 (13.1–214.3)

Visual deficit

72 (64.9)

67 (60.4)

0.58

Headache

66 (59.5)

56 (50.5)

0.22

Endocrinopathy

36 (32.4)

24 (21.6)

0.10

Fatigue/weakness

27 (24.3)

14 (12.6)

0.04

Sexual dysfunction

17 (15.3)

10 (9.0)

0.22

Presenting symptoms

Incidental

9 (8.1)

3 (2.7)

0.14

Unknown

11 (9.9)

31 (27.9)

0.001

Hypogonadism

11 (9.9)

11 (9.9)

1.00

Hypocortisolism

5 (4.5)

6 (2.4)

1.00

Hypothyroidism

21 (18.9)

8 (7.2)

0.02

Endocrine function*

Author Manuscript

Panhypopituitarism

10 (9.0)

8 (7.2)

0.81

No endocrinopathy

63 (56.8)

56 (50.5)

0.42

Unknown

12 (10.8)

31 (27.9)

0.002

Values are reported as number (%) of patients unless specified otherwise.
Boldface type indicates statistical significance.

*

These findings are not mutually exclusive, e.g., 1 patient could have 2 or more endocrine abnormalities that were separately counted.

Author Manuscript
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TABLE 2

Author Manuscript

Preoperative tumor characteristics
Characteristic

Early GKRS (≤6 mos)

Late GKRS (>6 mos)

p Value

Maximum tumor diameter, cm
1–1.9

10 (9.0)

11 (9.9)

1.00

2–2.9

39 (35.1)

23 (20.7)

0.02

3–4.0

28 (25.2)

21 (18.9)

0.33

>4.0

19 (17.1)

18 (16.2)

1.00

Unknown

15 (13.5)

38 (34.2)

0.001

<10 cm3

52 (46.8)

36 (32.4)

0.34

>10 cm3

37 (33.3)

35 (31.5)

Unknown

22 (19.8)

40 (36.0)

Suprasellar involvement

93 (83.8)

84 (75.7)

0.18

Cavernous sinus invasion

87 (78.4)

74 (66.7)

0.07

Null cell

52 (46.8)

61 (55.0)

0.28

Gonadotrophic

34 (30.6)

29 (26.1)

0.55

Silent corticotrophic

26 (23.4)

21 (18.9)

0.51

Thyrotrophic

3 (2.7)

3 (2.7)

1.00

Somatotrophic

3 (2.7)

4 (3.6)

1.00

Mean tumor volume

Author Manuscript

Involvement

Histopathology*

All values are presented as number (%) of patients. Boldface type indicates statistical significance.

Author Manuscript

*

These findings are not mutually exclusive, e.g., 13 patients had plurihormonal stains and each was counted separately.

Author Manuscript
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TABLE 3

Author Manuscript

Surgical treatment
Characteristic

Early GKRS (≤6 mos)

Late GKRS (>6 mos)

Preop

12.4

13.4

Postop

4.1

2.7

Size reduction, % change*

66.2

78.7

Preop information

100 (90.1)

82 (73.9)

Preop endocrinopathy

36 (36.0)

24 (29.3)

Postop information

111 (100)

111 (100)

Postop endocrinopathy

Tumor volume,

cm3

Endocrinopathy, no. of cases (%)

Author Manuscript

50 (45.0)

49 (44.1)

Resolved endocrinopathy

5 (4.5)

6 (5.4)

New endocrinopathy

11 (9.9)

8 (7.2)

No change endocrinopathy

31 (27.9)

18 (16.2)

*

Calculated as the average of each patient’s individual volume reduction.

Author Manuscript
Author Manuscript
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TABLE 4

Author Manuscript

Radiosurgical parameters
Parameter

Early GKRS (≤6 mos)

Late GKRS (>6 mos)

p Value

Margin dose, Gy

14.8 (10.0–25.0)

14.5 (5.0–25.0)

0.41

Maximum dose, Gy

29.4 (19.2–50.0)

28.3 (10.0–50.0)

0.18

Target volume, cm3

5.7 (0.0–57.3)

5.3 (0.3–37.6)

0.63

Maximum dose to optic chiasm, Gy

7.3 (1.0–12.3)

7.8 (1.2–12.6)

0.31

Maximum dose to optic tract, Gy

6.2 (1.5–12.0)

6.6 (1.2–12.0)

0.53

Maximum dose to optic nerve, Gy

7.5 (1.4–13.7)

7.2 (1.2–12.3)

0.44

All values are shown as the median (range).

Author Manuscript
Author Manuscript
Author Manuscript
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TABLE 5

Author Manuscript

Summary of patient outcomes
Outcome

Early GKRS (≤6 mos)

Late GKRS (>6 mos)

p Value

Yes

81 (83.5)

76 (93.8)

0.0375

No

16 (16.5)

5 (6.2)

Residual tumor at last follow-up*

Unknown

14

Tumor status after GKRS
Stable†

66 (81.5)

63 (82.9)

Growth

15 (18.5)

13 (17.1)

Growth >15%

11 (13.6)

8 (10.5)

0.63

Yes

64 (58.7)

61 (55.5)

0.68

No

45 (41.3)

49 (44.5)

2

1

New endocrinopathy after presentation§

19 (30.2)

15 (26.8)

0.84

New endocrinopathy after GKRS¶

6 (11.8)

5 (9.4)

0.76

Resolved endocrinopathy after presentation**

5 (13.9)

6 (25.0)

0.32

Resolved endocrinopathy after GKRS††

6 (10.0)

7 (12.1)

0.78

Hypogonadism

6 (5.4)

6 (5.4)

1.00

Hypocortisolism

3 (2.7)

6 (5.4)

0.49

Hypothyroidism

6 (5.4)

9 (8.1)

0.59

Panhypopituitarism

6 (5.4)

6 (5.4)

1.00

Hypogonadism

1 (0.9)

6 (5.4)

0.12

Hypocortisolism

5 (4.5)

2 (1.8)

0.45

Hypothyroidism

2 (1.8)

2 (1.8)

1.00

Panhypopituitarism

2 (1.8)

2 (1.8)

1.00

0.84

Post-GKRS endocrinopathy‡

Author Manuscript

Unknown

New endocrinopathy after GKRS§§

Author Manuscript

Resolved endocrinopathy after GKRS§§

All values are presented as number (%) of patients. Boldface type indicates statistical significance.

*

Shown as the percentage of patients with residual tumor information (97 patients in the early group and 81 patients in the late group).

†

Change of volume ≤ 15% after GKRS.

Author Manuscript

‡

Shown as the percentage of patients with known postop endocrinopathy information (109 patients in the early group and 110 in the late group).

§

Shown as the percentage of patients with no endocrinopathy at presentation (63 patients in the early group and 56 patients in the late group).

¶

Shown as the percentage of patients with no pre-GKRS endocrinopathy (51 patients in the early group and 53 patients in late group).

**

Shown as the percentage of patients with endocrinopathy at presentation (36 patients in the early group and 24 patients in the late group).
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††

Shown as the percentage of patients with pre-GKRS endocrinopathy (60 patients in the early group and 58 patients in the late group).

§§

Shown as the percentage of each cohort.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
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